国产精品视频免费看,精品熟女日韩中文十区,日本精品视频在线观看

CARsgen Therapeutics H1 2025 Financial Report CARsgen Financial statements Chinese Pharmaceutical Market CARsgen Therapeutics 2025 H1 results: revenue RMB 509.61M (+703.8% YoY), driven by BCMA CAR-T ZeKeze?. Pipeline updates include CT041 NDA acceptance, solid tumor CAR-T breakthroughs, and multiple allogeneic CAR-T developments.
Novartis' Triple Phase III Study Success: Dual-Action Anti-BAFF-R Monoclonal Antibody Triumph Novartis Autoimmune Autoimmune Drug Novartis' anti-BAFF-R antibody Ianalumab achieves breakthrough results in three Phase III trials for Sj?gren’s syndrome and immune thrombocytopenia, paving way for new autoimmune therapies.
Bayer $1.3 Billion Collaboration Agreement Bayer Kumquat Biosciences Bayer and Kumquat Biosciences announce a $1.3 billion global collaboration to develop and commercialize a KRAS G12D inhibitor, aiming to offer new treatment options for pancreatic, colorectal, and lung cancer patients.
First Global DPP1 Inhibitor Approved by FDA FDA Insmed The FDA has approved brensocatib, the world’s first DPP1 inhibitor, for treating non-cystic fibrosis bronchiectasis in patients aged 12+, marking a breakthrough in targeted respiratory therapies.
New Drug Approval Trends (2015-2024) by FDA, EMA, PMDA & Other Agencies Market Trend FDA EMA PMDA FDA Drug Approvals Trends in new drug approvals from 2015-2024 by six major regulatory agencies including FDA, EMA, PMDA, highlighting approval numbers, timelines, accelerated pathways, and patient experience data integration.
Gilead Q2 2025 Financial Report Financial statements Gilead Gilead's Q2 2025 results show strong HIV growth with Yeztugo approval but continued struggles in CAR-T therapies. Full-year guidance raised amid reliance on HIV business and strategic challenges ahead.
Sutro Biopharma H1 2025 Financial Report Financial statements Sutro?Biopharma Sutro Biopharma rebounds after major restructuring, posting 110% H1 2025 revenue growth. With strong cash reserves, strategic ADC pipeline advances, and key partnerships, it targets critical milestones through 2027.
BeOne(BeiGene) Q2 2025 Interim Financial Report BeiGene BeOne Financial statements Chinese Pharmaceutical Market BeiGene reported a net profit of 450 million yuan for H1 2025, marking its first interim profit since A-share listing. Strong product sales and revised revenue and margin forecasts signal sustainable growth.
2025 H1 Global Pharma Earnings Panorama Financial statements Market Trend Novartis Novo Nordisk Sanofi AstraZeneca A comprehensive analysis of global pharma earnings in H1 2025, highlighting innovation-driven growth, key players like Novartis, Novo Nordisk, AstraZeneca, Sanofi, and BeiGene, and trends shaping the industry’s future.
Eli Lilly 2025 H1 Report Financial statements Eli Lilly Eli Lilly's 2025 H1 revenue surged 41% to $28.29B, driven by tirzepatide sales hitting $14.7B. Mounjaro and Zepbound shine as blockbuster drugs, boosting Lilly's global pharmaceutical ranking.